Journal of Cardiovascular Echography

REVIEW ARTICLE
Year
: 2020  |  Volume : 30  |  Issue : 5  |  Page : 33--37

Atrial fibrillation, cancer and echocardiography


Maurizio Galderisi1, Roberta Esposito1, Regina Sorrentino1, Lucia La Mura1, Ciro Santoro1, Antonella Tufano2 
1 Department of Advanced Biomedical Sciences, University Federico II, Naples, Italy
2 Department of Clinical Medicine and Surgery, University Federico II, Naples, Italy

Correspondence Address:
Prof. Maurizio Galderisi
Department of Advanced Biomedical Sciences, University Federico II Hospital, Via Pansini 5, 80131 Naples
Italy

Nonvalvular atrial fibrillation (AF) is a relatively frequent arrhythmia in cancer patients; it is possibly due to direct effect of cancer or consequence of cancer therapies. AF creates important problems for both therapeutic management and prognosis in cancer patients. The anticoagulation of cancer patients presenting AF is a main issue because of the difficult balance between thromboembolic and bleeding risks, both elevated in this clinical setting. A comprehensive echo Doppler examination is mandatory to identify the eventual sources of emboli in left atrial (LA) cavity, mainly the transesophageal echocardiography (TEE), but also to predict the subsequent development of heart failure. This evaluation is particularly important to graduate anticoagulation and to prevent and manage symptoms/signs of heart failure. The performance of a TEE precardioversion is highly encouraged to detect possible thrombi in LA appendage. A careful assessment of LA size (LA volume index) and function (LA emptying fraction and/or LA strain) should always be planned to predict the possible recurrence of AF paroxysmal episodes. This is in fact a key action, not only from the cardiologic point of view but also for the oncologic perspectives in individual situations. Patients with larger left atrium and more impaired LA function should be addressed toward a less aggressive cancer treatment, with drugs which are not associated or are poorly related with the risk of AF development. A correct and comprehensive echocardiographic assessment could even induce the oncologist to change the cancer management balancing the oncologic and the cardiac risk.


How to cite this article:
Galderisi M, Esposito R, Sorrentino R, Mura LL, Santoro C, Tufano A. Atrial fibrillation, cancer and echocardiography.J Cardiovasc Echography 2020;30:33-37


How to cite this URL:
Galderisi M, Esposito R, Sorrentino R, Mura LL, Santoro C, Tufano A. Atrial fibrillation, cancer and echocardiography. J Cardiovasc Echography [serial online] 2020 [cited 2022 Sep 28 ];30:33-37
Available from: https://www.jcecho.org/article.asp?issn=2211-4122;year=2020;volume=30;issue=5;spage=33;epage=37;aulast=Galderisi;type=0